Search results
Results from the WOW.Com Content Network
Vancomycin is recommended to be administered in a dilute solution slowly, over at least 60 min (maximum rate of 10 mg/min for doses >500 mg) [21] due to the high incidence of pain and thrombophlebitis and to avoid an infusion reaction known as vancomycin flushing reaction. This phenomenon has been often clinically referred to as "red man syndrome".
One of the side effects is red man syndrome, an idiosyncratic reaction to bolus caused by histamine release. Some other side-effects of vancomycin are nephrotoxicity including kidney failure and interstitial nephritis, blood disorders including neutropenia, and deafness, which is reversible once therapy has stopped. Over 90% of the dose is ...
A drug of last resort (DoLR), also known as a heroic dose, [1] is a pharmaceutical drug which is tried after all other drug options have failed to produce an adequate response in the patient. Drug resistance , such as antimicrobial resistance or antineoplastic resistance , may make the first-line drug ineffective, especially in case of ...
Red man syndrome may refer to: Red man syndrome (Drug eruption) Erythroderma This page was last edited on 29 December 2019, at 21:53 (UTC). Text is available under ...
It belongs to the same class as vancomycin, the most widely used and one of the treatments available to people infected with methicillin-resistant Staphylococcus aureus (MRSA). [7] Dalbavancin is a semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides vancomycin and teicoplanin. [8]
The diagnosis of vancomycin-resistant Staphylococcus aureus (VRSA) is performed by performing susceptibility testing on a single S. aureus isolate to vancomycin. This is accomplished by first assessing the isolate's minimum inhibitory concentration (MIC) using standard laboratory methods, including disc diffusion, gradient strip diffusion, and automated antimicrobial susceptibility testing ...
The first documented strain with complete (>16 μg/ml) resistance to vancomycin, termed vancomycin-resistant S. aureus, appeared in the United States in 2002. [98] In 2011, a variant of vancomycin was tested that binds to the lactate variation and also binds well to the original target, thus reinstating potent antimicrobial activity. [ 99 ]
Vancomycin. Six different types of vancomycin resistance are shown by enterococcus: Van-A, Van-B, Van-C, Van-D, Van-E and Van-G. [4] The significance is that Van-A VRE is resistant to both vancomycin and teicoplanin, [5] Van-B VRE is resistant to vancomycin but susceptible to teicoplanin, [6] [7] and Van-C is only partly resistant to vancomycin.